The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.

Wilson JM, Lin Y, Luo MJ, Considine G, Cox AL, Bowsman LM, Robins DA, Haupt A, Duffin KL, Ruotolo G

Diabetes, obesity & metabolism11 Oct 2021Cited by 118 (Europe PMC)

PMID34542221PMCIDPMC9292792DOI10.1111/dom.14553PepBankPUB-34542221

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study25

21 results from studies that gave the peptide. 21 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 10 and 15 mg decreased YKL-40 levels from baseline at 26 weeks.
In plain wordsIn adults with type 2 diabetes, tirzepatide 10 and 15 mg lowered the inflammation marker YKL-40 from baseline.
Peptide
Tirzepatide
Outcome
DecreaseYKL-40 vs baseline
Study
n: not reported in source
Comparator
Baseline
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Studied dose
10 and 15 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
At 26 weeks, tirzepatide 10 and 15 mg decreased YKL-40 (also known as chitinase-3 like-protein-1), intercellular adhesion molecule 1 (ICAM-1), leptin, and growth differentiation factor 15 levels versus baseline, and YKL-40 and leptin levels versus placebo and dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222101
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 10 and 15 mg decreased ICAM-1 levels from baseline at 26 weeks.
In plain wordsIn adults with type 2 diabetes, tirzepatide 10 and 15 mg lowered the blood vessel marker ICAM-1 from baseline.
Peptide
Tirzepatide
Outcome
DecreaseICAM-1 vs baseline
Study
n: not reported in source
Comparator
Baseline
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Studied dose
10 and 15 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
At 26 weeks, tirzepatide 10 and 15 mg decreased YKL-40 (also known as chitinase-3 like-protein-1), intercellular adhesion molecule 1 (ICAM-1), leptin, and growth differentiation factor 15 levels versus baseline, and YKL-40 and leptin levels versus placebo and dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222102
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 10 and 15 mg decreased leptin levels from baseline at 26 weeks.
In plain wordsIn adults with type 2 diabetes, tirzepatide 10 and 15 mg lowered leptin levels from baseline.
Peptide
Tirzepatide
Outcome
DecreaseLeptin vs baseline
Study
n: not reported in source
Comparator
Baseline
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Studied dose
10 and 15 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
At 26 weeks, tirzepatide 10 and 15 mg decreased YKL-40 (also known as chitinase-3 like-protein-1), intercellular adhesion molecule 1 (ICAM-1), leptin, and growth differentiation factor 15 levels versus baseline, and YKL-40 and leptin levels versus placebo and dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222103
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 10 and 15 mg decreased growth differentiation factor 15 levels from baseline at 26 weeks.
In plain wordsIn adults with type 2 diabetes, tirzepatide 10 and 15 mg lowered the cell stress marker GDF15 from baseline.
Peptide
Tirzepatide
Outcome
DecreaseGrowth differentiation factor 15 vs baseline
Study
n: not reported in source
Comparator
Baseline
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Studied dose
10 and 15 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
At 26 weeks, tirzepatide 10 and 15 mg decreased YKL-40 (also known as chitinase-3 like-protein-1), intercellular adhesion molecule 1 (ICAM-1), leptin, and growth differentiation factor 15 levels versus baseline, and YKL-40 and leptin levels versus placebo and dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222104
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 10 and 15 mg decreased YKL-40 levels versus placebo and dulaglutide at 26 weeks.
In plain wordsIn adults with type 2 diabetes, tirzepatide 10 and 15 mg lowered YKL-40 more than placebo and dulaglutide.
Peptide
Tirzepatide
Outcome
DecreaseYKL-40 vs placebo and dulaglutide
Study
n: not reported in source
Comparator
Placebo and dulaglutide
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Studied dose
10 and 15 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
At 26 weeks, tirzepatide 10 and 15 mg decreased YKL-40 (also known as chitinase-3 like-protein-1), intercellular adhesion molecule 1 (ICAM-1), leptin, and growth differentiation factor 15 levels versus baseline, and YKL-40 and leptin levels versus placebo and dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222105
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 10 and 15 mg decreased leptin levels versus placebo and dulaglutide at 26 weeks.
In plain wordsIn adults with type 2 diabetes, tirzepatide 10 and 15 mg lowered leptin more than placebo and dulaglutide.
Peptide
Tirzepatide
Outcome
DecreaseLeptin vs placebo and dulaglutide
Study
n: not reported in source
Comparator
Placebo and dulaglutide
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Studied dose
10 and 15 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
At 26 weeks, tirzepatide 10 and 15 mg decreased YKL-40 (also known as chitinase-3 like-protein-1), intercellular adhesion molecule 1 (ICAM-1), leptin, and growth differentiation factor 15 levels versus baseline, and YKL-40 and leptin levels versus placebo and dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222106
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 15 mg decreased ICAM-1 levels versus placebo and dulaglutide.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg lowered ICAM-1 more than placebo and dulaglutide.
Peptide
Tirzepatide
Outcome
DecreaseICAM-1 vs placebo and dulaglutide
Study
n: not reported in source
Comparator
Placebo and dulaglutide
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Studied dose
15 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide 15 mg also decreased ICAM-1 levels versus placebo and dulaglutide, and high-sensitivity C-reactive protein (hsCRP) levels versus baseline and placebo, but not dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222107
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 15 mg decreased high-sensitivity C-reactive protein levels versus baseline and placebo.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg lowered the inflammation marker hsCRP compared with baseline and placebo.
Peptide
Tirzepatide
Outcome
DecreasehsCRP vs baseline and placebo
Study
n: not reported in source
Comparator
Baseline and placebo
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Studied dose
15 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide 15 mg also decreased ICAM-1 levels versus placebo and dulaglutide, and high-sensitivity C-reactive protein (hsCRP) levels versus baseline and placebo, but not dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222108
09HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 15 mg did not lower hsCRP levels significantly more than dulaglutide.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg did not lower hsCRP more than dulaglutide.
Peptide
Tirzepatide
Outcome
No significant changehsCRP vs dulaglutide
Study
n: not reported in source
Comparator
Dulaglutide
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Studied dose
15 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide 15 mg also decreased ICAM-1 levels versus placebo and dulaglutide, and high-sensitivity C-reactive protein (hsCRP) levels versus baseline and placebo, but not dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222109
10HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, GlycA levels were not significantly changed in any group.
In plain wordsIn adults with type 2 diabetes, GlycA levels did not change significantly in any group.
Peptide
Tirzepatide
Outcome
No significant changeGlycA not changed
Study
n: not reported in source
Comparator
Baseline and placebo
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Studied dose
1, 5, 10 or 15 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
GlycA, interleukin 6, vascular cell adhesion molecule 1, and N-terminal-pro hormone B-type natriuretic peptide levels were not significantly changed in any group.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222110
11HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, interleukin 6 levels were not significantly changed in any group.
In plain wordsIn adults with type 2 diabetes, interleukin 6 levels did not change significantly in any group.
Peptide
Tirzepatide
Outcome
No significant changeInterleukin 6 not changed
Study
n: not reported in source
Comparator
Baseline and placebo
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Studied dose
1, 5, 10 or 15 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
GlycA, interleukin 6, vascular cell adhesion molecule 1, and N-terminal-pro hormone B-type natriuretic peptide levels were not significantly changed in any group.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222111
12HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, vascular cell adhesion molecule 1 levels were not significantly changed in any group.
In plain wordsIn adults with type 2 diabetes, VCAM-1 levels did not change significantly in any group.
Peptide
Tirzepatide
Outcome
No significant changeVCAM-1 not changed
Study
n: not reported in source
Comparator
Baseline and placebo
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Studied dose
1, 5, 10 or 15 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
GlycA, interleukin 6, vascular cell adhesion molecule 1, and N-terminal-pro hormone B-type natriuretic peptide levels were not significantly changed in any group.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222112
13HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, N-terminal-pro hormone B-type natriuretic peptide levels were not significantly changed in any group.
In plain wordsIn adults with type 2 diabetes, NT-proBNP levels did not change significantly in any group.
Peptide
Tirzepatide
Outcome
No significant changeNT-proBNP not changed
Study
n: not reported in source
Comparator
Baseline and placebo
Analysis
Exploratory
Outcome group
Heart function · Cardiovascular
Studied dose
1, 5, 10 or 15 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
GlycA, interleukin 6, vascular cell adhesion molecule 1, and N-terminal-pro hormone B-type natriuretic peptide levels were not significantly changed in any group.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222113
14HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, YKL-40, hsCRP and ICAM-1 levels decreased rapidly within 4 weeks of tirzepatide 10 and 15 mg.
In plain wordsIn adults with type 2 diabetes, tirzepatide 10 and 15 mg lowered YKL-40, hsCRP and ICAM-1 within 4 weeks.
Peptide
Tirzepatide
Outcome
DecreaseTime course of YKL-40, hsCRP and ICAM-1 decrease
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Studied dose
10 and 15 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
YKL-40, hsCRP, and ICAM-1 levels rapidly decreased within 4 weeks of treatment with tirzepatide 10 and 15 mg
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222114
15HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the leptin decrease with tirzepatide 10 and 15 mg was more gradual and did not plateau by 26 weeks.
In plain wordsIn adults with type 2 diabetes, leptin fell more slowly with tirzepatide 10 and 15 mg and was still falling at 26 weeks.
Peptide
Tirzepatide
Outcome
DecreaseTime course of leptin decrease
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Studied dose
10 and 15 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
whereas the decrease in leptin levels was more gradual and did not plateau by 26 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222115
16HumanOther designEfficacy outcome
In patients with type 2 diabetes, YKL-40 levels at 26 weeks were higher with dulaglutide than with tirzepatide 10 mg.
In plain wordsIn patients with diabetes, YKL-40 levels were higher with dulaglutide than with tirzepatide 10 mg after 26 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseYKL-40
Study
n: not reported in source
Comparator
Tirzepatide 10 mg
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Studied dose
1.5 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
At 26 weeks, tirzepatide 10 and 15 mg decreased YKL-40 (also known as chitinase-3 like-protein-1), intercellular adhesion molecule 1 (ICAM-1), leptin, and growth differentiation factor 15 levels versus baseline, and YKL-40 and leptin levels versus placebo and dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222116
17HumanOther designEfficacy outcome
In patients with type 2 diabetes, YKL-40 levels at 26 weeks were higher with dulaglutide than with tirzepatide 15 mg.
In plain wordsIn patients with diabetes, YKL-40 levels were higher with dulaglutide than with tirzepatide 15 mg after 26 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseYKL-40
Study
n: not reported in source
Comparator
Tirzepatide 15 mg
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Studied dose
1.5 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
At 26 weeks, tirzepatide 10 and 15 mg decreased YKL-40 (also known as chitinase-3 like-protein-1), intercellular adhesion molecule 1 (ICAM-1), leptin, and growth differentiation factor 15 levels versus baseline, and YKL-40 and leptin levels versus placebo and dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222117
18HumanOther designEfficacy outcome
In patients with type 2 diabetes, leptin levels at 26 weeks were higher with dulaglutide than with tirzepatide 10 mg.
In plain wordsIn patients with diabetes, leptin levels were higher with dulaglutide than with tirzepatide 10 mg after 26 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseLeptin
Study
n: not reported in source
Comparator
Tirzepatide 10 mg
Analysis
Exploratory
Outcome group
Adipokines · Metabolic and weight
Studied dose
1.5 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
At 26 weeks, tirzepatide 10 and 15 mg decreased YKL-40 (also known as chitinase-3 like-protein-1), intercellular adhesion molecule 1 (ICAM-1), leptin, and growth differentiation factor 15 levels versus baseline, and YKL-40 and leptin levels versus placebo and dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222118
19HumanOther designEfficacy outcome
In patients with type 2 diabetes, leptin levels at 26 weeks were higher with dulaglutide than with tirzepatide 15 mg.
In plain wordsIn patients with diabetes, leptin levels were higher with dulaglutide than with tirzepatide 15 mg after 26 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseLeptin
Study
n: not reported in source
Comparator
Tirzepatide 15 mg
Analysis
Exploratory
Outcome group
Adipokines · Metabolic and weight
Studied dose
1.5 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
At 26 weeks, tirzepatide 10 and 15 mg decreased YKL-40 (also known as chitinase-3 like-protein-1), intercellular adhesion molecule 1 (ICAM-1), leptin, and growth differentiation factor 15 levels versus baseline, and YKL-40 and leptin levels versus placebo and dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222119
20HumanOther designEfficacy outcome
In patients with type 2 diabetes, ICAM-1 levels were higher with dulaglutide than with tirzepatide 15 mg.
In plain wordsIn patients with diabetes, ICAM-1 levels were higher with dulaglutide than with tirzepatide 15 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseICAM-1
Study
n: not reported in source
Comparator
Tirzepatide 15 mg
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Studied dose
1.5 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide 15 mg also decreased ICAM-1 levels versus placebo and dulaglutide, and high-sensitivity C-reactive protein (hsCRP) levels versus baseline and placebo, but not dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222120
21HumanOther designEfficacy outcome
In patients with type 2 diabetes, hsCRP did not differ significantly between dulaglutide and tirzepatide 15 mg.
In plain wordsIn patients with diabetes, hsCRP did not differ significantly between dulaglutide and tirzepatide 15 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeHigh-sensitivity C-reactive protein
Study
n: not reported in source
Comparator
Tirzepatide 15 mg
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Studied dose
1.5 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide 15 mg also decreased ICAM-1 levels versus placebo and dulaglutide, and high-sensitivity C-reactive protein (hsCRP) levels versus baseline and placebo, but not dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
Report a problemFND-3454222121

Studies that did not test the peptide alone4

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

22HumanNot a test of Dulaglutide (Trulicity) aloneOther designEfficacy outcome
In patients with type 2 diabetes, GlycA did not change significantly in any group, including dulaglutide.
In plain wordsIn patients with diabetes, GlycA did not change significantly in any group, including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeGlycA
Study
n: not reported in source
Comparator
Baseline
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Source sentences
Summary
GlycA, interleukin 6, vascular cell adhesion molecule 1, and N-terminal-pro hormone B-type natriuretic peptide levels were not significantly changed in any group.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3454222122
23HumanNot a test of Dulaglutide (Trulicity) aloneOther designEfficacy outcome
In patients with type 2 diabetes, interleukin 6 did not change significantly in any group, including dulaglutide.
In plain wordsIn patients with diabetes, interleukin 6 did not change significantly in any group, including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeInterleukin 6
Study
n: not reported in source
Comparator
Baseline
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Source sentences
Summary
GlycA, interleukin 6, vascular cell adhesion molecule 1, and N-terminal-pro hormone B-type natriuretic peptide levels were not significantly changed in any group.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3454222123
24HumanNot a test of Dulaglutide (Trulicity) aloneOther designEfficacy outcome
In patients with type 2 diabetes, vascular cell adhesion molecule 1 did not change significantly in any group, including dulaglutide.
In plain wordsIn patients with diabetes, vascular cell adhesion molecule 1 did not change significantly in any group, including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeVascular cell adhesion molecule 1
Study
n: not reported in source
Comparator
Baseline
Analysis
Exploratory
Outcome group
Inflammation markers · Cardiovascular
Source sentences
Summary
GlycA, interleukin 6, vascular cell adhesion molecule 1, and N-terminal-pro hormone B-type natriuretic peptide levels were not significantly changed in any group.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3454222124
25HumanNot a test of Dulaglutide (Trulicity) aloneOther designEfficacy outcome
In patients with type 2 diabetes, N-terminal-pro hormone B-type natriuretic peptide did not change significantly in any group, including dulaglutide.
In plain wordsIn patients with diabetes, this heart marker did not change significantly in any group, including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeN-terminal-pro hormone B-type natriuretic peptide
Study
n: not reported in source
Comparator
Baseline
Analysis
Exploratory
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
GlycA, interleukin 6, vascular cell adhesion molecule 1, and N-terminal-pro hormone B-type natriuretic peptide levels were not significantly changed in any group.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
Summary · context
In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3454222125

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.

Summary

Results from this study25

Studies that did not test the peptide alone4

Version history

Subjects

Publication types

MeSH terms

Keywords